RB1 and breast cancer: The essential role of CDKs in promoting cell cycle progression (through phosphorylation of Retinoblastoma (Rb)) established CDK4/6Is as a selective target therapy to influence outcomes in breast cancer, especially therapy-resistant breast cancer [1].